Evidence map›Paper›PMID 35800767›Full record

ArticleiScience2022

The immune checkpoint ICOSLG is a relapse-predicting biomarker and therapeutic target in infant t(4;11) acute lymphoblastic leukemia.

Marius Külp, Anna Lena Siemund, Patrizia Larghero, Alissa Dietz, Julia Alten, Gunnar Cario, Cornelia Eckert, Aurélie Caye-Eude, Hélène Cavé, Michela Bardini and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in iScience, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Marius KülpDiagnostic Center of Acute Leukemia (DCAL), Institute of Pharmaceutical Biology, Goethe-University, University of Frankfurt, Max-von-Laue-Str. 9, Frankfurt am Main, Germany.
Anna Lena SiemundDiagnostic Center of Acute Leukemia (DCAL), Institute of Pharmaceutical Biology, Goethe-University, University of Frankfurt, Max-von-Laue-Str. 9, Frankfurt am Main, Germany.
Patrizia LargheroDiagnostic Center of Acute Leukemia (DCAL), Institute of Pharmaceutical Biology, Goethe-University, University of Frankfurt, Max-von-Laue-Str. 9, Frankfurt am Main, Germany.
Alissa DietzDiagnostic Center of Acute Leukemia (DCAL), Institute of Pharmaceutical Biology, Goethe-University, University of Frankfurt, Max-von-Laue-Str. 9, Frankfurt am Main, Germany.
Julia AltenDepartment of Pediatrics, University Medical Center Schleswig-Holstein, Campus Kiel, Germany.
Gunnar CarioDepartment of Pediatrics, University Medical Center Schleswig-Holstein, Campus Kiel, Germany.
Cornelia EckertDepartment of Pediatric Hematology and Oncology, Charité-Universitätsmedizin Berlin, Berlin, Germany.
Aurélie Caye-EudeDépartement de Génétique, Hôpital Robert Debré, Assistance Publique des Hôpitaux de Paris (AP-HP), Paris, France.
Hélène CavéDépartement de Génétique, Hôpital Robert Debré, Assistance Publique des Hôpitaux de Paris (AP-HP), Paris, France.
Michela BardiniCentro Ricerca Tettamanti, Pediatrics, University of Milan-Bicocca, Fondazione Monza e Brianza per il Bambino e la sua Mamma (MBBM)/San Gerardo Hospital, Monza, Italy.
Giovanni CazzanigaCentro Ricerca Tettamanti, Pediatrics, University of Milan-Bicocca, Fondazione Monza e Brianza per il Bambino e la sua Mamma (MBBM)/San Gerardo Hospital, Monza, Italy.
Paola De LorenzoStatistical Section, Pediatric Clinic, University of Milano-Bicocca, Monza, Italy.
Maria Grazia ValsecchiCenter of Bioinformatics, Biostatistics and Bioimaging, University of Milano-Bicocca, Monza, Italy.
Laura DiehlInstitute for Transfusion Medicine and Immunohematology, Goethe University, Frankfurt am Main, Germany.
Halvard BonigInstitute for Transfusion Medicine and Immunohematology, Goethe University, Frankfurt am Main, Germany.
Claus MeyerDiagnostic Center of Acute Leukemia (DCAL), Institute of Pharmaceutical Biology, Goethe-University, University of Frankfurt, Max-von-Laue-Str. 9, Frankfurt am Main, Germany.
Rolf MarschalekDiagnostic Center of Acute Leukemia (DCAL), Institute of Pharmaceutical Biology, Goethe-University, University of Frankfurt, Max-von-Laue-Str. 9, Frankfurt am Main, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The most frequent genetic aberration leading to infant ALL (iALL) is the chromosomal translocation t(4;11), generating the fusion oncogenes

Indexed as

CancerHealth sciencesImmunology

Identifiers

PMID35800767
PMCPMC9253708

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.